MedTrace Logo

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

NCT04729543 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-12-04

No results posted yet for this study

Summary

Single-centre, first-in-man phase I/II trial to demonstrate safety and efficacy of MAGE-C2/HLA-A2 TCR T cells (MC2 TCR T cells) in advanced melanoma (MEL) and head-and-neck carcinoma (HNSCC).

Conditions

Interventions

BIOLOGICAL

Adoptive therapy with autologous MC2 TCR T cells

Adoptive therapy with autologous MC2 TCR T cells combined with AZA/VP

Sponsors & Collaborators

  • Ludwig Institute for Cancer Research

    collaborator OTHER

  • Dutch Cancer Society

    collaborator OTHER

  • Stichting Coolsingel Rotterdam grant

    collaborator UNKNOWN

  • Jan Ivo Stichting grant

    collaborator UNKNOWN

  • Erasmus Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-20
Primary Completion
2024-12-20
Completion
2027-10-20

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04729543 on ClinicalTrials.gov